Stentrode is the only implantable brain-computer interface that does not require open brain surgery and is currently in clinical trials SAN FRANCISCO & NEW YORK & MELBOURNE, Australia--(BUSINESS WIRE) ...

California Start-up Synchron recently published its study and findings in the success of the "Stentrode" Brain chips implanted in the blood vessels of paralyzed and disabled patients to help them ...

Synchron, the startup behind an FDA breakthrough neuroprosthesis device that aims to give patients with paralysis the ability to control digital devices with their thoughts, has been cleared by the ...

SAN FRANCISCO and NEW YORK CITY and MELBOURNE, Australia, Sept. 20 2019 /PRNewswire/ -- Synchron Inc. today announced the first successful clinical implantation of the Stentrode®, a minimally-invasive ...

Synchron is the only company to receive FDA approval to conduct clinical trials of a permanently implanted BCI. The company’s novel BCI technology leverages the blood vessels as the natural highways ...

For the first time, doctors are preparing to test a brain-computer interface that can be implanted onto a human brain, no open surgery required. The Stentrode, a neural implant that can let paralyzed ...

One year down, a lifetime to go. New results from Synchron’s first human study of its brain-computer interface system—a permanent, stent-like implant—found that one year after the device’s placement, ...

US-based Synchron has secured $200m in a Series D funding round to drive the commercial rollout of its Stentrode brain-computer interface (BCI) platform and aid in the creation of next-generation ...

Synchron Inc.'s recent $200 million raise for its Stentrode brain-computer interface platform comes at a pivotal time for the technology. Advances in BCI development, ongoing clinical trials and ...

Neurovascular bioelectronics medicine company Synchron Inc. has received good news in the form of a breakthrough device designation for its Stentrode. The U.S. FDA granted the designation for the ...